Holen Sie sich die Stockscreener-App
9.16
8.46%
0.71
Handel nachbörslich:
9.25
0.09
+0.98%
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent Biosolutions donates thousands of NARCAN Nasal Spray units across the U.S. since 2021 - Traders Union
Emergent BioSolutions (EBS) Secures ACAM2000 Approval in Saudi A - GuruFocus
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - marketscreener.com
Saudi Arabia approves smallpox and mpox vaccine for people at high risk - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Stock Quote - The Chronicle-Journal
Global governments turn to Emergent Biosolutions for crisis health preparedness - Traders Union
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
EBS Technical Analysis | Trend, Signals & Chart Patterns | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
EBS Stock Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. Common Stock (NY: EBS - FinancialContent
SABS: SAB-142 progresses in phase II-B with robust funding and regulatory clarity, targeting type 1 diabetes - TradingView
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance - MSN
Emergent BioSolutions Inc. (EBS): Investor Outlook with a Promising 31.43% Potential Upside - DirectorsTalk Interviews
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Harsanyi Zsolt - Moomoo
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
MSN Money - MSN
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Fowler Neal Franklin - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Zoon Kathryn C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Richard Ronald - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director FOWLER JOHN D JR - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director White Marvin L - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director DeGolyer Donald W - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Dayal Sujata Tyagi - Moomoo
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director Dayal sells $115,610 in stock By Investing.com - Investing.com South Africa
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com South Africa
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):